clinical trial · NCT06959095
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
GlaxoSmithKline·phase3·recruiting·n = 981
Pulmonary Disease, Chronic ObstructiveDepemokimabPlacebo
brief summary
Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.
started
Jun 20, 2025
primary completion
Aug 20, 2029
completion
Aug 20, 2029
last updated
Oct 8, 2025
official title
A Randomized, Double-Blind, Placebo- Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Depemokimab In Adult Participants With COPD With Type 2 Inflammation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol